437 related articles for article (PubMed ID: 18309948)
1. Prognostic stratification of stage IIIA-N2 non-small-cell lung cancer after induction chemotherapy: a model based on the combination of morphometric-pathologic response in mediastinal nodes and primary tumor response on serial 18-fluoro-2-deoxy-glucose positron emission tomography.
Dooms C; Verbeken E; Stroobants S; Nackaerts K; De Leyn P; Vansteenkiste J
J Clin Oncol; 2008 Mar; 26(7):1128-34. PubMed ID: 18309948
[TBL] [Abstract][Full Text] [Related]
2. Significance of a new fluorodeoxyglucose-positive lesion on restaging positron emission tomography/computed tomography after induction therapy for non-small-cell lung cancer.
Collaud S; Lardinois D; Tischler V; Steinert HC; Stahel R; Weder W
Eur J Cardiothorac Surg; 2012 Mar; 41(3):612-6. PubMed ID: 22219415
[TBL] [Abstract][Full Text] [Related]
3. Long-term survival of 42 patients with resected N2 non-small-cell lung cancer: the impact of 2-(18)F-fluoro-2-deoxy-D-glucose positron emission tomogram mediastinal staging.
Barnett S; Baste JM; Murugappan K; Tog C; Berlangieri S; Scott A; Seevanayagam S; Knight S
Eur J Cardiothorac Surg; 2011 Jan; 39(1):96-101. PubMed ID: 20580245
[TBL] [Abstract][Full Text] [Related]
4. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer.
Hoekstra CJ; Stroobants SG; Smit EF; Vansteenkiste J; van Tinteren H; Postmus PE; Golding RP; Biesma B; Schramel FJ; van Zandwijk N; Lammertsma AA; Hoekstra OS
J Clin Oncol; 2005 Nov; 23(33):8362-70. PubMed ID: 16293866
[TBL] [Abstract][Full Text] [Related]
5. Prospective comparative study of integrated positron emission tomography-computed tomography scan compared with remediastinoscopy in the assessment of residual mediastinal lymph node disease after induction chemotherapy for mediastinoscopy-proven stage IIIA-N2 Non-small-cell lung cancer: a Leuven Lung Cancer Group Study.
De Leyn P; Stroobants S; De Wever W; Lerut T; Coosemans W; Decker G; Nafteux P; Van Raemdonck D; Mortelmans L; Nackaerts K; Vansteenkiste J
J Clin Oncol; 2006 Jul; 24(21):3333-9. PubMed ID: 16849747
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of primary tumor FDG uptake for occult mediastinal lymph node involvement in clinically N2/N3 node-negative non-small cell lung cancer.
Trister AD; Pryma DA; Xanthopoulos E; Kucharczuk J; Sterman D; Rengan R
Am J Clin Oncol; 2014 Apr; 37(2):135-9. PubMed ID: 23111361
[TBL] [Abstract][Full Text] [Related]
7. Pattern and predictors of occult mediastinal lymph node involvement in non-small cell lung cancer patients with negative mediastinal uptake on positron emission tomography.
Al-Sarraf N; Aziz R; Gately K; Lucey J; Wilson L; McGovern E; Young V
Eur J Cardiothorac Surg; 2008 Jan; 33(1):104-9. PubMed ID: 17977738
[TBL] [Abstract][Full Text] [Related]
8. FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology.
Ryu JS; Choi NC; Fischman AJ; Lynch TJ; Mathisen DJ
Lung Cancer; 2002 Feb; 35(2):179-87. PubMed ID: 11804691
[TBL] [Abstract][Full Text] [Related]
9. Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIa-N2 non-small-cell lung cancer: a prospective pilot study. The Leuven Lung Cancer Group.
Vansteenkiste JF; Stroobants SG; De Leyn PR; Dupont PJ; Verbeken EK
Ann Oncol; 1998 Nov; 9(11):1193-8. PubMed ID: 9862049
[TBL] [Abstract][Full Text] [Related]
10. Restaging of mediastinal nodes with transbronchial needle aspiration after induction chemoradiation for locally advanced non-small cell lung cancer.
Kunst PW; Lee P; Paul MA; Senan S; Smit EF
J Thorac Oncol; 2007 Oct; 2(10):912-5. PubMed ID: 17909353
[TBL] [Abstract][Full Text] [Related]
11. Incidence of occult mediastinal node involvement in cN0 non-small-cell lung cancer patients after negative uptake of positron emission tomography/computer tomography scan.
Gómez-Caro A; Garcia S; Reguart N; Arguis P; Sanchez M; Gimferrer JM; Marrades R; Lomeña F
Eur J Cardiothorac Surg; 2010 May; 37(5):1168-74. PubMed ID: 20116273
[TBL] [Abstract][Full Text] [Related]
12. Value of F-18-fluorodeoxyglucose positron emission tomography after induction therapy of locally advanced bronchogenic carcinoma.
Hellwig D; Graeter TP; Ukena D; Georg T; Kirsch CM; Schäfers HJ
J Thorac Cardiovasc Surg; 2004 Dec; 128(6):892-9. PubMed ID: 15573074
[TBL] [Abstract][Full Text] [Related]
13. Increasing the accuracy of 18F-FDG PET/CT interpretation of "mildly positive" mediastinal nodes in the staging of non-small cell lung cancer.
Moloney F; Ryan D; McCarthy L; McCarthy J; Burke L; Henry MT; Kennedy MP; Hinchion J; McSweeney S; Maher MM; O'Regan K
Eur J Radiol; 2014 May; 83(5):843-7. PubMed ID: 24581594
[TBL] [Abstract][Full Text] [Related]
14. Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival.
Decaluwé H; De Leyn P; Vansteenkiste J; Dooms C; Van Raemdonck D; Nafteux P; Coosemans W; Lerut T
Eur J Cardiothorac Surg; 2009 Sep; 36(3):433-9. PubMed ID: 19502079
[TBL] [Abstract][Full Text] [Related]
15. Are discordant positron emission tomography and pathological assessments of the mediastinum in non-small cell lung cancer significant?
Tandberg DJ; Gee NG; Chino JP; D'Amico TA; Ready NE; Coleman RE; Kelsey CR
J Thorac Cardiovasc Surg; 2013 Oct; 146(4):796-801. PubMed ID: 23870158
[TBL] [Abstract][Full Text] [Related]
16. Mediastinoscopy might not be necessary in patients with non-small cell lung cancer with mediastinal lymph nodes having a maximum standardized uptake value of less than 5.3.
Lee BE; Redwine J; Foster C; Abella E; Lown T; Lau D; Follette D
J Thorac Cardiovasc Surg; 2008 Mar; 135(3):615-9. PubMed ID: 18329480
[TBL] [Abstract][Full Text] [Related]
17. Volume-Based Assessment With 18F-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer.
Hyun SH; Ahn HK; Ahn MJ; Ahn YC; Kim J; Shim YM; Choi JY
AJR Am J Roentgenol; 2015 Sep; 205(3):623-8. PubMed ID: 26295651
[TBL] [Abstract][Full Text] [Related]
18. The additional value of FDG PET imaging for distinguishing N0 or N1 from N2 stage in preoperative staging of non-small cell lung cancer in region where the prevalence of inflammatory lung disease is high.
Turkmen C; Sonmezoglu K; Toker A; Yilmazbayhan D; Dilege S; Halac M; Erelel M; Ece T; Mudun A
Clin Nucl Med; 2007 Aug; 32(8):607-12. PubMed ID: 17667432
[TBL] [Abstract][Full Text] [Related]
19. Non-small cell lung cancer: prognostic importance of positive FDG PET findings in the mediastinum for patients with N0-N1 disease at pathologic analysis.
Xie L; Saynak M; Veeramachaneni NK; Fried DV; Jagtap MR; Chiu WK; Higginson DS; Lawrence MV; Khandani AH; Qaqish BF; Chen RC; Marks LB
Radiology; 2011 Oct; 261(1):226-34. PubMed ID: 21813742
[TBL] [Abstract][Full Text] [Related]
20. Is there any maximum standardized uptake value variation among positron emission tomography scanners for mediastinal staging in non-small cell lung cancer?
Iskender I; Kadioglu SZ; Kosar A; Atasalihi A; Kir A
Interact Cardiovasc Thorac Surg; 2011 Jun; 12(6):965-9. PubMed ID: 21441257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
